NAMS

Newamsterdam Pharma Company N.v.

A biotech company developing a once-daily oral pill to lower "bad" LDL cholesterol in people at risk of heart disease. Its lead drug, obicetrapib, met its goals in three late-stage trials and is also being studied for Alzheimer's disease. Founded in 2019 by Dutch lipidologist John Kastelein and investor Forbion, the company's name bridges its Dutch roots and US ambitions. The drug itself was famously rescued from the scrap heap after drug giant Amgen shelved it, reviving a treatment rivals had abandoned.